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The first lymphoid-restricted progeny of hematopoi-
etic stem cells (HSCs) are lymphoid-primed multipo-
tent progenitors (LMPPs), which have little erythro-
myeloid potential but retain lymphoid, granulocyte,
and macrophage differentiation capacity. Despite
recent advances in the identification of LMPPs, the
transcription factors essential for their generation re-
main to be identified. Here, we demonstrated that the
E2A transcription factors were required for proper
development of LMPPs. Within HSCs and LMPPs,
E2A proteins primed expression of a subset of lym-
phoid-associated genes and prevented expression
of genes that are not normally prevalent in these cells,
including HSC-associated and nonlymphoid genes.
E2A proteins also restricted proliferation of HSCs,
MPPs, and LMPPs and antagonized differentiation
of LMPPs toward the myeloid fate. Our results reveal
that E2Aproteinsplay acritical role in supporting lym-
phoid specification from HSCs and that the reduced
generation of LMPPs underlies the severe lympho-
cyte deficiencies observed in E2A-deficient mice.
INTRODUCTION
Lymphocyte development from hematopoietic stem cells (HSCs)
is accompanied by a loss of self-renewal capacity and a progres-
sive restriction of developmental potential. The pathway to the
lymphocyte fate involves the generation of multipotent progeni-
tors (MPPs) and lymphoid-primed multipotent progenitors
(LMPPs) that have lymphoid as well as granulocyte and macro-
phage progenitor (GMP) potential but little or no megakaryocyte
and erythrocyte progenitor (MEP) potential, respectively (Adolfs-
son et al., 2005; Lai et al., 2005). However, the precise stage in
which MEP potential is lost remains controversial (Forsberg
et al., 2006). LMPPs are precursors to common lymphoid
progenitors (CLPs), which have lost GMP potential but retain
multilineage lymphoid-differentiation capacity when placed in
an appropriate microenvironment (Kondo et al., 1997). LMPPs
also differentiate into early T lymphocyte progenitors (ETPs),
which undergo T lymphocyte lineage specification upon activa-tion of Notch receptors by Notch ligands in the thymus (Allman
et al., 2003; Sambandam et al., 2005). Although the molecular
mechanisms for generation of committed B or T lymphocytes
are beginning to be revealed, a major unanswered question is
how the multipotent progeny of HSCs initiate differentiation
toward lymphoid fate.
HSCs, MPPs, and LMPPs are lineageSca-1+c-kithi (LSK) cells
that can be distinguished by the increasing expression of the
transmembrane receptor fms-like tyrosine kinase 3 (Flt3) (Adolfs-
son et al., 2001; Adolfsson et al., 2005). Upregulation of Flt3 is
associated with decreased megakaryocyte- (Mk) and erythro-
cyte (E)-associated gene expression. Lymphoid-associated
gene expression is initiated in LMPPs, indicating priming of the
lymphoid gene program (Igarashi et al., 2002; Mansson et al.,
2007). A small number of transcriptional regulators have been
implicated in the development or function of LMPPs. The zinc-
finger transcription factors encoded by the Ikzf1 (Ikaros) gene
are dispensable for the generation of LMPPs but required for
high expression of Flt3 and subsequent lymphocyte differentia-
tion (Yoshida et al., 2006). The Ets-related transcription factor
PU.1, encoded by Sfpi1, is increased in a subset of LMPPs,
and Flt3hi LSKs are absent in the liver of Sfpi1/ embryos and
the bone marrow (BM) of adult mice with a conditional deletion
of Sfpi1 (Arinobu et al., 2007; Dakic et al., 2005; Iwasaki et al.,
2005). However, it remains to be determined whether PU.1 is re-
quired for development of functional LMPPs or, like Ikaros, is re-
quired specifically for Flt3 expression (Dakic et al., 2005; Iwasaki
et al., 2005). Aside from these two factors, little is known about
the transcriptional regulators that specify differentiation toward
LMPPs in multipotent progenitors (Nutt and Kee, 2007).
Lymphoid priming involves the induction of lymphoid genes,
including Rag1, Dntt, and Igh-6, which are known targets of
the basic helix-loop-helix (bHLH) transcription factors E12 and
E47, encoded by Tcfe2a (E2A) (Kee and Murre, 1998, 2001;
Mansson et al., 2007). The E-box-binding transcription factors
(E proteins) function in cell-fate specification and differentiation
in diverse cell types in both invertebrates and vertebrates
(Massari and Murre, 2000). The E2A proteins have been charac-
terized extensively as regulators of B and T lymphocyte develop-
ment and are thought to function in specification of these
lineages from lymphoid-restricted multipotent progenitors (Nutt
and Kee, 2007; Welner et al., 2008). E2A proteins specify the B
lymphocyte fate by regulating the essential transcription factor
encoded by the early B cell factor 1 (Ebf1) gene, in collaboration
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E2A Directs Lymphoid Specificationwith PU.1 and interleukin (IL)-7 receptor-activated STAT5 (Dias
et al., 2005; Kee and Murre, 1998; Kikuchi et al., 2005; Medina
et al., 2004; Roessler et al., 2007; Seet et al., 2004). Although
no B lymphocytes are generated in Tcfe2a/ mice, T lympho-
cytes develop, albeit in reduced numbers (Bain et al., 1997a;
Bain et al., 1994; Zhuang et al., 1994). In vitro studies suggest
that E2A proteins regulate expression of the essential T lympho-
cyte specification factor Notch1 and collaborate with Notch1 to
activate target genes such asHes1 (Ikawa et al., 2006). However,
the requirements for E2A in vivo and in vitro differ because E2A is
indispensable for T lymphopoiesis in vitro on OP9 stromal cells
expressing the Notch ligand Delta-like 1, but T cells develop
in vivo with a partial arrest at the DN1-to-DN2 transition (i.e., after
the initial requirement for Notch1) (Bain et al., 1997a; Ikawa et al.,
2006; Kee et al., 2002). Therefore, the role of E2A proteins in early
T lymphocyte development in vivo remains to be fully under-
stood.
Multipotent hematopoietic progenitor cell lines can be gener-
ated from Tcfe2a/ BM, suggesting a role for E2A proteins in
preventing expansion of multipotent cells and promoting differ-
entiation (Ikawa et al., 2004). However, aside from their known
roles in the regulation of B and T lymphocyte genes, a function
for E2A proteins in earlier stages of hematopoiesis has not
been reported. We show here that E2A proteins promote devel-
opment of LMPPs and are required to establish an appropriate
LMPP transcriptome. Importantly, E2A appears to be dispens-
able for extinction of the MEP fate en route to LMPPs but
restricts proliferation and further myeloid differentiation in
LMPPs. Our results reveal a dose-dependent requirement for
E2A proteins at the earliest stages of lymphoid specification
and indicate that reduced thymopoiesis in Tcfe2a/ mice initi-
ates from a failure to produce sufficient numbers of functional
BM-derived LMPPs.
RESULTS
A Dose-Dependent Requirement for E2A
in Development of CLPs and ETPs
E2A proteins are required for B cell development in part because
they promote expression of EBF1 (Kee and Murre, 1998; Seet
et al., 2004). This observation contributed to the prevailing
view that E2A proteins play a critical role at the CLP-to-pro-B-
lymphocyte transition, during which EBF1 first becomes essen-
tial (Pongubala et al., 2008; Welner et al., 2008). A similar view
has developed regarding the requirements for E2A in T cell
development, during which these proteins are thought to be es-
sential for commitment to the T lymphocyte lineage, despite
recent evidence implicating E2A in the regulation of Notch1,
which is required already by the ETP stage (Bain et al., 1997a;
Ikawa et al., 2006; Kee et al., 2002; Rothenberg, 2007). However,
it has not been determined whether E2A proteins function at ear-
lier stages of lymphohematopoiesis. Therefore, we undertook
a rigorous quantitative analysis of lymphocyte-progenitor popu-
lations in Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/ mice by flow
cytometry. Consistent with a previous report (Borghesi et al.,
2005), we found a significant reduction in the percentage and to-
tal number of CLPs in Tcfe2a/ as compared to Tcfe2a+/+ BM
(90%, p < 0.001). Interestingly, however, we also found a reduced
number of Tcfe2a+/ CLPs (60%, p < 0.001), indicating a dose-
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(Figures 1A and 1B). Analysis of Lin thymocytes revealed
a dose-dependent requirement for E2A in development of
ETPs and DN2 thymocytes (Figures 1C and 1D). However, the
number of Tcfe2a+/ DN3 thymocytes is indistinguishable from
that of the wild-type (WT), whereas Tcfe2a/ DN3 cells remain
reduced, although the number was variable (Figures 1C and
1D). The reduced number of ETPs in Tcfe2a+/ and Tcfe2a/
mice was not revealed in previous studies because of contami-
nation of the conventional DN1 subset with non-T lineage cells,
which are not affected by deletion of E2A (Allman et al., 2003;
Bain et al., 1997a; Kee et al., 2002). Therefore, we conclude
that there is a dose-dependent requirement for Tcfe2a during
development of CLPs, ETPs, and DN2 thymocytes.
A Dose-Dependent Requirement for E2A
in Development of LMPPs
E2A proteins are widely expressed in BM multipotent hemato-
poietic progenitors (Figure S1 available online) (Zhuang et al.,
2004), and our data indicate that E2A may be required upstream
of CLPs and ETPs. Therefore, we undertook a quantitative anal-
ysis of BM LSK cells, including HSCs, MPPs, and LMPPs in
Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/mice. We found that the fre-
quency and total number of LSK cells was decreased in Tcfe2a+/
and Tcfe2a/ compared to Tcfe2a+/+ BM (Figures 2A and 2B).
The number of HSCs and MPPs was not significantly different
between each of these strains, although a consistent mild
decrease was observed (Figures 2A and 2B). In contrast, the
number of LMPPs was significantly reduced in both Tcfe2a+/
(68%, p = 0.008) and Tcfe2a/ (84%, p = 0.002) BM compared
to Tcfe2a+/+ BM (Figures 2A, 2B, and 2C). The decreased fre-
quency of LMPPs did not appear to be the consequence of a re-
quirement for E2A in transcription of the Flt3 gene because there
is no compensatory increase in the number of Flt3 or Flt3lo
LSKs (Figure 2B). In addition, we have found no evidence that
E2A can induce Flt3 mRNA in MPPs under conditions in which
E2A can induce other potential target genes (see below). We
also found a reduced frequency of VCAM-1 LSKs in Tcfe2a+/
and Tcfe2a/ BM (Figure 2A), further supporting the conclusion
that LMPPs are reduced in Tcfe2a+/ and Tcfe2a/ mice (Lai
and Kondo, 2006; Lai et al., 2005). In contrast, erythromyeloid
progenitors were not decreased, but rather, they were slightly
increased in Tcfe2a+/ and Tcfe2a/ mice (Figure S2). Taken
together, our data indicate that E2A proteins play a dose-depen-
dent role in the development of LMPPs, which represent the
earliest lymphoid-primed progeny of HSCs.
E2A Proteins Antagonize Proliferation of HSCs, MPPs,
and LMPPs
E proteins are necessary for pro-B lymphocyte proliferation (Kee,
2005; Seet et al., 2004), although high concentrations of E2A can
restrain proliferation (Engel and Murre, 2004). Therefore, we con-
sidered the possibility that LMPPs are reduced in number in
Tcfe2a+/ and Tcfe2a/ mice because these cells or their pre-
cursors require E2A for expansion. To test this possibility, we ex-
amined BrdU incorporation in Tcfe2a+/+ and Tcfe2a/ BM LSK
subpopulations after 24 hr of in vivo labeling. Surprisingly, we
found that Tcfe2a/ LSKs incorporated more BrdU than
Tcfe2a+/+ LSKs (Figure 3A). Importantly, all Tcfe2a/ LSK
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E2A Directs Lymphoid SpecificationFigure 1. A Dose-Dependent Requirement for E2A in the Generation of CLPs, ETPs, and DN2 Cells
(A) Lin BM cells from Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/ mice were analyzed for surface expression of c-kit and IL-7Ra (upper panels), and the c-kitloIL-7Ra+
subpopulation was analyzed for expression of Sca-1 and Flt3 (lower panels) by flow cytometry. CLPs are Linc-kitloIL-7Ra+Sca-1+Flt3+.
(B) Relative number of CLPs in BM of adult Tcfe2a+/ (gray) and Tcfe2a/ (white) mice as compared to wild-type mice (black; set to 1). A minimum of five mice
were analyzed in each group. Error bars represent the mean ± SD; **p < 0.01.
(C) Surface expression of c-kit and CD25 on Lin thymocytes; numbers represent the percentage of cells in each gate.
(D) Relative number of ETPs, DN2, and DN3 cells in the thymus of adult Tcfe2a+/ (gray) and Tcfe2a/ (white) mice as compared to wild-type mice (black;
set to 1). A minimum of five mice were analyzed in each group. Error bars represent the mean ± SD; ** p < 0.01.subsets incorporated more BrdU than the corresponding
Tcfe2a+/+ populations (Figure 3B). Therefore, the reduced num-
ber of LMPPs in Tcfe2a+/ and Tcfe2a/ BM was not a conse-
quence of reduced proliferation of LMPPs or their precursors.
Indeed, E2A proteins appeared to limit proliferation of these mul-
tipotent cells. Importantly, after in vitro culture, Tcfe2a/ and
Tcfe2a+/+ LSKs showed a similar or slightly reduced frequency
of apoptotic cells as measured by annexin V binding, indicating
that the lack of E2A is not leading to increased cell death
(Figure 3C). These data lead us to suggest that Tcfe2a/ LSK
cells preferentially adopt a fate other than LMPP.
E2A Proteins Are Required for Proper Lymphoid Gene
Expression in LMPPs
To further address the requirements for E2A in the development
of multipotent lymphoid progenitors, we examined the transcrip-
tome of purified Tcfe2a+/+ and Tcfe2a/ LMPPs. Differentially
expressed genes were further characterized on the basis of their
expression in Tcfe2a+/+ HSCs, as well as in long-term (LT)
HSC, preGM, CLPs, megakaryocyte progenitors (MkP), and
pre-colony-forming unit (CFU)-E (Pronk et al., 2007). Comparing
overall gene expression in Tcfe2a+/+ and Tcfe2a/ LMPPs, thePearson correlation was 0.99 as compared to 0.94 when either
LMPP sample was compared to Tcfe2a+/+ HSCs. Therefore,
the few Flt3hi LSKs in Tcfe2a/ mice are LMPPs, and any alter-
ations in gene expression are unlikely to result from differences in
cell composition. A total of 47 genes failed to be appropriately
expressed (i.e., decreased by >50%) in Tcfe2a/ LMPPs, indi-
cating that these genes are directly or indirectly regulated by
E2A (Figure 4A). Twenty-six of these genes were more highly ex-
pressed in CLPs than in other progenitor populations, indicating
that E2A proteins play a major role in establishing the lymphoid-
associated gene-expression signature. Among these genes
were multiple known E2A targets, including Rag1, Il7r, Dntt,
Igh-6, and Notch1 (Figure 4A). Some of these lymphoid-associ-
ated genes were found to be expressed in HSCs and dependent
on E2A, indicating that they are already being primed in the HSC
population in an E2A-dependent manner (Table 1). These genes
are candidates for genes that influence lymphoid specification
(Georgopoulos, 2002).
In addition to the set of known E2A target genes, multiple
genes were decreased in Tcfe2a/ LMPPs that have not been
previously shown to be E2A dependent (Figure 4A and
Figure S3). One of these genes is Ccr9, which encodes the
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E2A Directs Lymphoid SpecificationFigure 2. A Dose-Dependent Requirement for E2A in the Generation of LMPPs
(A) Lin BM cells from Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/ mice were analyzed for surface expression of c-kit and Sca-1 (upper panels). The LSK subset was
analyzed for expression of c-kit and Flt3 (middle panels) or Flt3 and VCAM-1 (lower panels). Numbers represent the percent of cells in the indicated gate. LMPPs
are LSK Flt3hi and LSK VCAM-1.
(B) The total number of HSCs (black), MPPs (gray), and LMPPs (white) in Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/ mice is shown, and the sum of these populations is
the total number of LSK cells.
(C) Number of HSCs, MPPs, LMPPs, and CLPs in Tcfe2a+/ (gray) and Tcfe2a/ (white) mice relative to the WT (black; set to 1). A minimum of six mice were
analyzed in each group. Error bars represent the mean ± SD; **p < 0.01.receptor for the chemokine CCL25, and we confirmed that Ccr9
and Notch1 mRNA were reduced in E2A+/ and E2A/ LMPPs
by quantitative PCR (Figure 4B). Importantly, Ccr9, but not Flt3
mRNA, could be induced by E47 in Tcfe2a/ progenitors cul-
tured in vitro (Figure 4C). CCR9 is expressed on a small popula-
tion of LMPPs that possess efficient in vivo thymus-repopulating
capacity (Benz and Bleul, 2005; Schwarz et al., 2007; Scimone
et al., 2006), and this subpopulation is severely decreased in
both Tcfe2a+/ and Tcfe2a/ mice (92%, p = 0.021 and 96%,
p = 0.014, respectively) (Figures 4D and 4E). Therefore, the
loss of Ccr9-expressing LMPPs is likely to contribute to the
reduced number of ETPs observed in Tcfe2a+/ and Tcfe2a/
mice.
E2A Does Not Regulate Expression of Key Lymphoid
Transcription Factors in LMPPs
The microarray analysis of Tcfe2a+/+ and Tcfe2a/ LMPPs
revealed a central role for E2A in lymphoid priming. Importantly,
however, E2A proteins were not required for expression of the
key lymphoid transcription factors Ikaros, PU.1, and Gfi1, which
are essential for lymphocyte development beyond the LMPP
stage (Figure 5A) (Hock et al., 2004; Medina et al., 2004; Yoshida
et al., 2006; Zeng et al., 2004). Nonetheless, known targets of
PU.1 and Ikaros, including Dntt and Il7r, were not expressed
appropriately (Figure 4A). An analysis of the genomic DNA sur-
rounding the transcription start sites of CLP-associated E2A-de-
pendent genes revealed that all but two of these genes (90%)
have conserved (between human and mouse) potential binding
220 Immunity 29, 217–227, August 15, 2008 ª2008 Elsevier Inc.sites for E2A (Figure 5B). Moreover, more than 60% of these
genes had potential binding sites for E2A, Ikaros, and/or
PU.1 (Figure 5B). In contrast, within a set of randomly selected
genes that were expressed equivalently in Tcfe2a+/+ and
Tcfe2a/ LMPPs, 40% lacked potential E2A binding sites and
only 25% had sites for E2A, Ikaros, and/or PU.1. Taken together,
these data indicate that E2A is required for Ikaros and PU.1 to
promote expression of at least a subset of their target genes
in LMPPs.
E2A Proteins Restrict the GMP Potential,
but Not the MEP Potential, of LMPPs
Although E2A is required for the expression of multiple LMPP-as-
sociated genes, we found that there is a set of genes that is ex-
pressed more abundantly in Tcfe2a/ compared to Tcfe2a+/+
LMPPs, including genes expressed in HSCs, preGM, MkP, and
pre-CFU-E (Figure 4A and Figure S3). A subset of these genes
is also expressed more abundantly in Tcfe2a/HSCs, indicating
that these alterations in gene expression initiate within the HSC
compartment and may influence lymphoid specification (Table
1). These data also show that the few Tcfe2a/ LMPPs that de-
velop have a substantially altered transcriptome and fail to
appropriately extinguish a set of non-LMPP-associated genes.
Our data indicate that in the absence of E2A, there is a progres-
sive loss of lymphoid progenitor potential that initiates within
the HSC or MPP compartment and that becomes apparent by
the time of the emergence of LMPPs. The transition from HSC
to LMPP is associated with a progressive loss of MEP
Immunity
E2A Directs Lymphoid SpecificationFigure 3. E2A Proteins Restrict HSC, MPP, and LMPP Proliferation
(A) BrdU incorporation in BM LSKs as determined after 24 hr of in vivo exposure to BrdU. LSKs were analyzed for surface expression of Flt3 and intracellular BrdU;
numbers indicate the percentage of BrdU+ LSKs. The graph summarizes results of five independent experiments.
(B) Percentage of HSCs, MPPs, and LMPPs that were BrdU+ in Tcfe2a+/+ and Tcfe2a/ mice, respectively.
(C) Representative FACS analysis for annexin-V and PI staining on cultured HSC, MPP, or LMPPs cells. Numbers represent the percentage of cells in each plot
that are positive for annexin V, as shown in the gated region.developmental potential (Adolfsson et al., 2005; Mansson et al.,
2007). Therefore, we questioned whether the loss of E2A influ-
ences the erythromyeloid potential of MPPs or LMPPs. To test
this possibility, we examined the ability of single Tcfe2a+/+ and
Tcfe2a/ HSCs, MPPs, and LMPPs to give rise to Mk in vitro
under conditions that efficiently support Mk and other myeloid
lineage development (Figure 6A). As reported previously (Adolfs-
son et al., 2005; Arinobu et al., 2007), we found that WT HSCs,
MPPs, and LMPPs have a high cloning efficiency but that LMPPs
do not develop into Mk under these conditions (Figures 6B and
6C). Importantly, sorted Tcfe2a/ HSCs, MPPs, and LMPPs
showed a similar restriction of Mk potential (Figure 6B). However,
Tcfe2a/ LMPPs had a higher clongenic potential than their WT
counterparts, and individual Tcfe2a/ clones were markedly
larger than WTs (Figure 6D). Tcfe2a/ MPP colonies were
also, on average, larger than Tcfe2a+/+ MPP-derived colonies
(Figure 6D). Using a methycellulose-based assay, we also
observed that Flt3+ LSKs from Tcfe2a/mice have an increased
clonogenic potential compared to Tcfe2a+/+ cells (Figure 6D).
Wright-Giemsa staining of individual clones under both culture
conditions revealed that WT and Tcfe2a/ LMPPs gave rise
only to granulocytes and/or macrophages (Figure 6C and
Figure S4). We note that in Tcfe2a/ LMPP clones, we also
detected an increase in atypical granulocytes, which appear to
be cells undergoing apoptosis, suggesting that loss of E2A
may influence the rate of granulocyte differentiation or the life-
span of granulocytes under these conditions (Figure S4). Taken
together, our data support a model in which E2A proteins
promote differentiation toward the lymphoid fate and, in the
absence of E2A, MPPs and LMPPs preferentially adopt the
GMP fate. This model is consistent with previous studies show-
ing that E2A proteins can induce lymphoid-lineage conversion ina macrophage cell line and that E2A represses macrophage
development from MPPs in vitro (Bhalla et al., 2008; Kee and
Murre, 1998).
DISCUSSION
We have identified a requirement for E2A proteins in supporting
the development of LMPPs from HSCs. E2A proteins are essen-
tial for the initial priming of a subset of lymphoid-associated
genes, some of which are already detected within HSCs. In the
absence of E2A, key lymphoid-promoting transcription factors,
such as PU.1, Ikaros, and Gfi1, are expressed appropriately;
however, E2A is necessary for these genes to activate some of
their targets in LMPPs. Moreover, we found that E2A-dependent
lymphoid genes frequently have conserved potential binding
sites for PU.1 and/or Ikaros, indicating that these transcription
factors may cooperatively regulate the lymphoid gene program.
Nonetheless, the role of E2A extends beyond the induction of
lymphoid genes because Tcfe2a/ HSCs and LMPPs showed
aberrant expression of genes that are not normally expressed
in these cells. We also found that E2A proteins restrict pro-
liferation of HSCs, MPPs, and LMPPs and antagonize GMP
differentiation from LMPPs in vitro. Our data indicate that the first
essential function of E2A proteins in lymphocyte development is
to support the development of a lymphoid-primed cell popula-
tion that is capable of further restriction to specific lymphoid
fates.
Our data reveal a severe loss of LMPPs in both Tcfe2a+/ and
Tcfe2a/mice. However, unlike Ikaros and PU.1, which are also
required for the development of Flt3hi LSKs, we found no
evidence that E2A proteins directly regulate Flt3 (Medina et al.,
2004; Yoshida et al., 2006). Flt3 mRNA was not differentially
Immunity 29, 217–227, August 15, 2008 ª2008 Elsevier Inc. 221
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E2A Directs Lymphoid SpecificationFigure 4. Analysis of the Tcfe2a+/+ and
Tcfe2a/ LMPP Transcriptome
(A) Clustering of genes that are differentially
expressed in replicate samples (one per column)
of Tcfe2a+/+ and Tcfe2a/ LMPPs (Affymetrix
MOE430 2.0 arrays). Expression of these genes
in Tcfe2a+/+ HSCs is shown for comparison. The
clustering includes all genes with expression
levels >50 in at least one of the four LMPP arrays
and differing by a factor of two (with a lower 90%
confidence bound of fold change). Each row
corresponds to one unique identifier, and a subset
of CLP-associated genes is indicated (see
Figure S3 for complete list of genes). The right-
most clustering shows the lineage association of
these differentially expressed genes in LT-HSC,
pre-GM, CLP, MkP, and pre-CFU-E (as defined
in Pronk et al. [2007]). Red indicates high expres-
sion levels, blue indicates low expression levels,
and white indicates intermediate expression
levels.
(B) Relative expression of Notch1 and Ccr9 mRNA
in purified Tcfe2a+/ and Tcfe2a/ LMPPs, as
compared to Tcfe2a+/+ progenitors (normalized
to Hprt and set to 1), determined by quantitative
polymerase chain reaction (QPCR). Error bars rep-
resent the mean ± SD of replicate experiments.
(C) QPCR analysis of Ccr9 and Flt3 mRNA in
Tcfe2a/ fetal-liver multipotent progenitors, 36 hr
after transduction with control or E47-producing
retrovirus. One of two experiments is shown. Error
bars represent the mean ± SD.
(D) Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/ LSKs analyzed for surface expression of Flt3 and CCR9. CCR9 expression in Tcfe2a+/+ LK-S cells is shown for compar-
ison. One of three experiments is shown.
(E) Absolute number of CCR9+ LMPPs in the BM (femurs and tibias) of Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/ mice. Error bars represent the mean ± SD; * p < 0.05.expressed in Tcfe2a+/+ and Tcfe2a/ LMPPs, and there was no
compensatory increase in the number of Flt3 or Flt3lo LSKs in
Tcfe2a/ mice, as might be predicted if LMPPs lacking Flt3
were present. Moreover, ectopic expression of E2A in Tcfe2a/
progenitors does not alter Flt3 mRNA, even though Ccr9
mRNA is induced. Using loss of VCAM-1 as a distinguishing
feature of LMPPs, we also found that LMPPs were reduced in
Tcfe2a/mice (Lai and Kondo, 2007; Lai et al., 2005). Therefore,
the loss of Flt3hi LSKs in Tcfe2a+/ and Tcfe2a/ mice reflects
a decline in LMPP numbers. Although E2A proteins do not regu-
late Flt3 mRNA, it is possible that Flt3 signaling regulates E2A
function. Flt3 could regulate E2A by phosphorylation or indirectly
through Flt3-dependent downregulation of class II bHLH pro-
teins, such as stem cell leukemia (SCL) protein, also known as
T lymphocyte acute lymphoblastic leukemia protein 1 (TAL1)
(Adolfsson et al., 2005; Neufeld et al., 2000).
E2A proteins clearly play a major role in the development of
LMPPs. However, a small number of LMPPs develop in
Tcfe2a+/ and Tcfe2a/mice, and these cells are able to gener-
ate T lymphocytes, but not B lymphocytes, in vivo. A possible ex-
planation for the development of these few LMPPs is that they
rely on E protein activity provided by the E proteins HEB and
E2-2. The E proteins are functionally redundant and can cooper-
ate with other transcription factors to activate E2A target genes,
even when expressed at low concentrations (Seet et al., 2004;
Zhuang et al., 1998). Nonetheless, a number of lymphoid genes
fail to be appropriately expressed in Tcfe2a/ LMPPs, including
Rag1, Il7r, Dntt, Ets1, and Ccr9. It is unlikely that these particular
222 Immunity 29, 217–227, August 15, 2008 ª2008 Elsevier Inc.genes regulate the development of LMPPs because LMPPs
develop in mice that lackRag1,Ccr9, Il7r, or Ets1 (B.L.K., unpub-
lished data and Schwarz et al. [2007]). Regardless, our findings
indicate that within LMPPs, E2A is required for proper expres-
sion of a large subset of lymphoid genes. Interestingly, a subset
of these genes can be detected in HSCs and are E2A dependent,
indicating that the lymphoid gene program is beginning priming
at a substantially earlier developmental stage than previously
appreciated. This observation is consistent with other studies
that have identified lineage-associated transcripts in HSCs
(Manaia et al., 2000; Ye et al., 2003; Yoshida et al., 2008) and
raises the possibility that this subset of E2A-dependent genes
may play a role in specifying the lymphoid fate (Georgopoulos,
2002).
In addition to regulating lymphoid-associated genes, E2A was
necessary to prevent expression of a set of genes not normally
found in LMPPs. Interestingly, a subset of these genes was
also increased in E2A/ HSCs. This observation, in conjunction
with the decline in MPP and LMPP numbers, indicates that the
function of E2A extends beyond lymphoid priming. Indeed,
loss of E2A was associated with an increased proliferation of
HSCs, MPPs, and LMPPs, as well as increased clongenic poten-
tial and GMP differentiation in LMPPs, effects that are unlikely to
be attributed to a lack of lymphoid priming. The loss of LMPPs in
Tcfe2a+/ and Tcfe2a/ mice did not appear to be due to a fail-
ure of expansion or increased cell death. Rather, fewer cells were
undergoing lymphoid specification and instead adopted the
GMP fate. A role for E2A proteins in restricting GMP
Immunity
E2A Directs Lymphoid SpecificationTable 1. E2A-Dependent Lymphoid Gene Expression in HSCs
Probe Set Gene Name E2A+/+ HSC (mean)* E2A/ HSC (mean)*
Fold Decrease in E2A/ HSC
(95% confidence interval)
1449757_x_at Dntt 1370.74 135.61 10.11 (8.92–11.66)
1450545_a_at Dntt 302.53 37.24 8.12 (6.43–10.80)
1427351_s_at Igh-6 662.31 112.67 5.88 (5.37–6.46)
1427329_a_at Igh-6 262.57 50.12 5.24 (4.92–5.6)
1422851_at Hmga2 291.41 79.50 3.67 (2.99–4.74)
1420805_at Mylc2pl 87.59 25.35 3.45 (3.26–3.69)
1455570_x_at Cnn3 132.12 40.25 3.28 (2.87–3.81)
1436759_x_at Cnn3 139.58 42.86 3.26 (2.90–3.68)
1449310_at Ptger2 51.64 16.57 3.12 (2.47–3.86)
1436836_x_at Cnn3 186.31 62.16 3.00 (2.62–3.43)
1450780_s_at Hmga2 218.78 73.10 2.99 (2.49–3.73)
1426725_s_at Ets1 143.95 72.09 2.00 (1.62–2.46)
1419872_at Csf1r 229.91 116.53 1.97 (1.73–2.22)
1418634_at Notch1 608.16 311.76 1.95 (1.82–2.10)
Probe Set Gene Name E2A+/+ HSC (mean)* E2A/ HSC (mean)*
Fold increase in E2A/ HSC
(95% confidence interval)
1434465_x_at Vldlr 369.8 757.21 2.05 (1.66–2.44)
1439814_at Atp8b4 199.22 415.49 2.09 (1.82–2.44)
1435893_at Vldlr 127.66 275.66 2.16 (1.66–3.08)
1434278_at Mtm1 229.19 505.02 2.21 (1.96–2.52)
1417900_a_at Vldlr 92.11 210.58 2.29 (1.95–2.75)
1457139_at Auts2 41.51 133.81 3.22 (2.71–3.94)
A total of 30 unique genes were differentially expressed in Tcfe2a/ HSCs (Flt3 LSKs) as compared to Tcfe2a+/+ HSCs (21 decreased and 9
increased).
* Mean of two replicate samples.differentiation is consistent with a previous report demonstrating
that E12 can induce lymphoid gene expression and repress my-
eloid traits in a macrophage cell line (Kee and Murre, 1998) and
our recent finding that ectopic expression of E12 in Tcfe2a/
MPPs promotes B lymphocyte development and represses
macrophage development in vitro (Bhalla et al., 2008). Therefore,
E2A proteins, possibly in collaboration with other lymphoid tran-
scription factors, promote lymphoid specification.Although E2A proteins promote lymphoid specification, they
are not required for restriction of Mk potential in LMPPs. There-
fore, E2A proteins do not promote lymphomyeloid specification
at the expense of erythromyeloid specficiation, even though
CMPs and MEPs are slightly increased in Tcfe2a/ mice. This
increase may be a result of the increased proliferation of
Tcfe2a/ HSCs, which could lead to greater erythromyeloid
output over time. Interestingly, however, E2A proteins are highlyFigure 5. Expression of Key Lymphoid Transcription Factors in the Absence of E2A
(A) QPCR for Ikzf1, Sfpi1, and Gfi1 mRNA in purified Tcfe2a+/+, Tcfe2a+/, and Tcfe2a/ LMPPs (normalized to Hprt and amount in Tcfe2a+/+ LMPPs set to 1).
Error bars represent the mean ± SD.
(B) Distribution of conserved potential E2A, Ikaros, and PU.1 binding sites in the promoters (7.5 kb to +2.5 kb) of E2A-dependent lymphoid-associated genes or
a set of randomly selected LMPP genes whose expression is not E2A dependent. Binding sites were identified with rVISTA through the ECR Browser. ‘‘None’’
indicates no binding sites for E2A, PU.1, or Ikaros (black). ‘‘Single’’ indicates a binding site for only one factor; in the E2A-dependent case, these were all E2A-
binding sites, whereas in the random genes, they were equally mixed (dark gray). ‘‘E2A+other’’ indicates a binding site for E2A with PU.1 and/or Ikaros (light gray).
‘‘Other’’ indicates a binding site for PU.1 and/or Ikaros but not E2A (white).
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E2A Directs Lymphoid SpecificationFigure 6. Tcfe2a/ LMPPs Restrict the MEP Fate but Show Increased Myeloid Clonogenic Potential
(A) HSCs, MPPs, and LMPPs were isolated from the BM LSK population by cell sorting, and single cells were seeded in wells of Terasaki plates in conditions
supporting multilineage myeloid differentiation.
(B) Frequency of Tcfe2a+/+ and Tcfe2a/ clones giving Mk containing (black) or GM only (white) colonies in vitro. One of four representative experiments
is shown.
(C) Representative examples of colonies that were positive (left) or negative (right) for the presence of megakaryocytes (Mk). Wright-Giemsa staining of the
Mk-containing clone (bottom). ‘‘G’’ denotes granulocyte; ‘‘M’’ denotes macrophage.
(D) Number of clones generated from 180 single-cell cultures of Tcfe2a+/+ or Tcfe2a/HSCs, MPPs, or LMPPs. Color-coding from blue to red represents the size
of colonies from smallest (three to nine cells) to largest (90%–100% of well). The majority of MPP- and all LMPP-derived colonies were GM (see Figure S4A). One
of three representative experiments is shown.
(E) Number of clonable Tcfe2a+/+ (black) and Tcfe2a/ (white) LSKFlt3+ progenitors determined at day 7 of culture in methylcellulose (mean of three replicate
wells ± SD; *p < 0.05). One of three representative experiments is shown.expressed in erythromyeloid progenitors and can function as di-
merizing partners for SCL and Lyl1, which play an essential role
in Mk and E differentiation (Lecuyer and Hoang, 2004). There-
fore, appropriate regulation of E2A-protein homodimer and het-
erodimer formation may play a major role in allowing the differen-
tiation of these two pathways downstream of HSCs. At the
present time, it is not known whether there is a single progenitor
cell that makes a binary decision regarding the erythromyeloid or
lymphomyeloid fate, and recent studies suggest that these deci-
sions may be temporally segregated (Arinobu et al., 2007).
Therefore, considerable experimentation is still required to re-
veal the basic mechanisms dissociating these two branches of
the hematopoietic system and the role of lymphoid-promoting
transcription factors in restricting MEP differentiation.
Our data also provide insight into the relationship between
E2A and Notch1 and the regulation of T lymphocyte specifica-
tion. We showed that E2A was required in vivo for optimal ex-
pression of Notch1 mRNA in LMPPs and HSCs. Although the re-
224 Immunity 29, 217–227, August 15, 2008 ª2008 Elsevier Inc.duced amount of Notch1 does not appear to prevent T cell
development, it may nonetheless decrease the ‘‘fitness’’ of these
ETPs in vivo, as observed with Notch1+/ ETPs (Tan et al., 2005).
We found that the number of ETPs in Tcfe2a+/ and Tcfe2a/
mice was reduced in proportion to the decrease in LMPPs, given
the potential amplifying effect of the lack of CCR9 (Schwarz
et al., 2007). Therefore, our data suggest that the primary cause
of the reduced number of DN thymocytes in Tcfe2a+/ and
Tcfe2a/ mice is the failure to produce sufficient BM-derived
lymphoid-primed progenitors. However, the fact that Tcfe2a/
thymocytes frequently fail to recover to WT numbers by the
DN3 stages suggests that there may be additional defects in
these cells that prevent appropriate T cell development.
The data we have presented indicate that E2A proteins func-
tion in the transcriptional network that specifies the lymphomye-
loid fate in multipotent progenitors and in the lymphoid-priming
within these cells and their precursors. These newly identified
functions for E2A, together with its role in regulation of B and T
Immunity
E2A Directs Lymphoid Specificationlymphocyte-specific gene expression, resembles the known
functions of the Drosophila homolog of E2A, daughterless, in
neurogenesis, during which it is required to establish the identity
of cells with potential to develop into neuronal lineages (the
proneural field) and subsequently functions within the proneural
field to activate lineage-specifying genes (Bertrand et al., 2002).
Similar functions have been described for class II bHLH proteins,
which require E proteins to mediate transcription, in determina-
tion and differentiation of olfactory neurons in mammals (Cau
et al., 2002). Therefore, the E proteins may play universal func-
tions in cell-fate determination and differentiation.
EXPERIMENTAL PROCEDURES
Mice
Mice were housed at the University of Chicago Animal Resource Center, and
experiments were performed in accordance with the guidelines of the National
Institutes of Health and protocols approved by the Institutional Animal Care
and Use Committee. C57Bl/6 E47/ mice (here referred to as Tcfe2a/)
and genotyping protocols have been described previously (Bain et al.,
1997b). Mice were analyzed between 6 and 12 weeks of age.
Flow Cytometry and Sorting
Cells were harvested from thymus or BM and stained with specific combina-
tions of antibodies (see Table S1) purchased from BD Biosciences and eBio-
sciences, with the exception of CCR9 (R&D Systems). Lineage antibodies
were biotinylated (revealed with streptavidin-PECy5.5), and the remainders
were conjugated to FITC, PE, PE-Cy7, or APC. Cells were analyzed with
a FACS Canto and FlowJo (Tree Star) software or sorted with a FACS Aria.
For sorting, lineage+ cells were first depleted by magnetic-activated cell
separation with streptavidin MicroBeads (Miltenyi Biotec) according to the
manufacturer’s instructions. Dead cells were stained with PI and excluded
by electronic gating. Intracellular staining was performed as described previ-
ously with purified hE47 monoclonal antibody (BD Biosciences) (Engel et al.,
2001). We used negative-staining controls to distinguish negative and positive
populations. LSK gates were determined with the strategy described by
Kondo et al. (1997). Flt3 gates were determined with the strategy described
by Adolfsson et al. (2005).
Determination of Cell Numbers in Each Progenitor Population
We determined the absolute number of viable cells in the BM (two femurs and
two tibias) or thymus by trypan blue exclusion. We multiplied this number by
the percentage of Lin cells in the viable cell gate (PI) and then by the percent-
age of cells in each subgate thereafter to determine the absolute number of
progenitors in each subpopulation per mouse. For BM progenitors, we then
further normalized this number to 50 3 106 total BM cells to minimize differ-
ences due to animal size. Relative cell numbers were calculated by dividing
the number of cells in each subpopulation by the number of cells in that
same subpopulation in WT mice (therefore, WT = 1 for each cell population
and in each set of mice analyzed). Statistical significance was assessed by
the Student’s t test.
In Vivo BrdU-Incorporation Assay
Mice were injected intraperitoneally with 1 mg BrdU per 6 g of body weight (BD
Biosciences) 24 hr and 12 hr prior to analysis of BM subpopulations by flow
cytometry. BrdU staining was performed with the FITC BrdU Flow Kit (BD
Biosciences) according to the manufacturer’s instructions.
In Vitro Apoptosis Assay
Sorted HSC, MPP, and LMPP were cultured in media lacking serum for 20 hr.
Staining was performed with the Annexin-V-FITC Apoptosis Detection Kit (BD
Biosciences) according to the manufacturer’s instructions.
Affymetrix Gene Expression and Data Analysis
RNA was extracted with the RNeasy Micro Kit (QIAGEN), labeled, amplified,
and hybridized to MOE430 2.0 Affymetrix gene-expression arrays accordingto Affymetrix standard protocols. Probe-level expression values were calcu-
lated with RMA (Irizarry et al., 2003). Further analysis was performed with
dChip (www.dchip.org).
Transcription-factor binding sites conserved between human and mouse
genomic sequences were identified in the promoters of E2A-dependent lym-
phoid-associated genes and a set of randomly selected genes with rVISTA
(Dubchak and Ryaboy, 2006). The promoters were defined as the region
7.5 kb to +2.5 kb of the transcription start site as defined by gene annotation
in the ECRBrowser (http://ecrbrowser.dcode.org/). The E2A-dependent lym-
phoid-associated genes examined were as follows: Apcdd1, Arpp21, Blnk,
Ccr9,Cnn3,Dntt, Ets1, Fgf13,Gsn,Hmga2, Il7r,Klf3,Mylc2pl,Notch1,Ptger2,
Rag1, Slc9a9, and Slc27a2. The randomly selected genes were as follows:
Appbp1, Cdk4, Cdk9, Cog2, Ctsc, Entpd5, Gdi2, Hnrpa2, Mrps14, Ndufb7,
Rplp1, Rpl14, sdfr1, Smc6l1, Snrpa1, Snsx3, Timeless, Tpd52l2, Uba52, and
Ywhab.
Quantitative PCR
RNA was extracted with the RNeasy Micro Kit and cDNA was prepared with
random primers and SuperScriptIII reverse transcriptase (Invitrogen), accord-
ing to the manufacturer’s instructions. QPCR reactions were performed in trip-
licate with iQ SYBR Green Supermix (Biorad) and detected by MyiQ Single
Color Real-Time PCR System (Biorad). Most primers (see Table S2) amplify
multi-exon sequences; for the remainder, DNaseI (QIAGEN) treatment and
a nonRT negative control were included.
Retroviral Transduction
Sorted Linc-kithighCD27+ fetal-liver progenitors were spinoculated (2 hr at
2500 rpm) in the presence of 5 mg/ml polybrene with pCS and pCS-E47-ER
(Sayegh et al., 2003) retroviral supernatants produced in Plat-E cells. Trans-
duced cells were cultured on OP9-DL1 stroma in the presence of c-kit-ligand,
Flt3-ligand, IL7, and 1 mM 4-hydroxytamoxifen for 36 hr.
In Vitro Evaluation of Erythromyeloid Differentiation Potential
Single BM HSCs, MPPs, and LMPPs were seeded in Terasaki plates (180 cells
per population in each experiment) and cultured as previously described
(Mansson et al., 2007). Wells were scored with an inverted light microscope
on days 9–12 of culture for clonal growth, clone size, and frequency of Mk.
Mk detection was confirmed by Wright-Giemsa staining of cytospin prepara-
tions. Fifty BM Flt3+ LSK cells were seeded per well in six-well plates, in
1.1 ml MethoCult 03434 (StemCell Technologies) supplemented with 50 ng/mL
Flt3-ligand and 10 ng/mL thrombopoietin (PeproTech). Clonal growth was
evaluated on day 7.
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